Quick Dispatch:
Your tirzepatide surpass trials New Dual Incretin Agonist for Type 2 Diabetes orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your tirzepatide surpass trials New Dual Incretin Agonist for Type 2 Diabetes ships.
Need Help?
Questions about tirzepatide surpass trials New Dual Incretin Agonist for Type 2 Diabetes, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for tirzepatide surpass trials New Dual Incretin Agonist for Type 2 Diabetes in your area.
Media Centre
29.49
Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program | Cardiovascular Diabetology
27.25
💡 New insight in diabetes care: In patients with T2DM and ASCVD, the SURPASS-CVOT trial found that tirzepatide was noninferior to dulaglutide for major cardiovascular events (12.2% vs 13.1%; HR 0.92). What
28.70
SURPASS-CVOT trial: For patients with high-risk type 2 diabetes, the effect of tirzepatide, a dual agonist of the GLP-1 and glucose-dependent insulinotropic polypeptide receptors, on cardiovascular outcomes is uncertain. Research is summarized
21.01
Annals
23.45
Media Centre
23.35
Incidence of mild and severe side effects of tirzepatide in SURPASS 1-5...
20.19
